跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
陳 錦華
教授
,
大數據科技及管理研究所
合聘教授
,
應用流行病學碩士學位學程
合聘教授
,
國際生技醫療管理博士學位學程
成員
,
臺北醫學大學胸腔醫學研究中心
https://orcid.org/0000-0002-3130-4125
電子郵件
jh_chen
tmu.edu
tw
h-index
2706
引文
29
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2004
2025
每年研究成果
概覽
指紋
網路
專案
(13)
研究成果
(130)
資料集
(7)
類似的個人檔案
(9)
指紋
查看啟用 Jin-Hua Chen 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Meta-Analysis
100%
Systematic Review
63%
Positron Emission Tomography-Computed Tomography
48%
Positron Emission Tomography
44%
Fluorodeoxyglucose F 18
40%
Hazard Ratio
36%
Cohort Analysis
34%
Positron Emission Tomography
31%
Randomized Controlled Trial
27%
Disease
25%
Computer Assisted Tomography
23%
Fluorodeoxyglucose
21%
Sensitivity and Specificity
21%
Kawasaki Disease
19%
Coronary Artery Aneurysm
19%
Autoimmune Disease
17%
Lung Cancer
16%
Injury
15%
Autoimmune Rheumatic Disease
14%
Fluorine-18
14%
Sjoegren Syndrome
12%
Rheumatoid Arthritis
12%
Systemic Lupus Erythematosus
12%
Genetic Variability
11%
Maturity Onset Diabetes of the Young
10%
Infection
10%
Lymph Node
9%
Head and Neck Cancer
9%
Non Small Cell Lung Cancer
9%
Head and Neck Squamous Cell Carcinoma
9%
Colorectal Cancer
9%
Parkinson's Disease
9%
Chinese Herbal Medicine
9%
Network Meta-Analysis
9%
Diagnostic Performance
9%
Odds Ratio
9%
Malignant Neoplasm
9%
Overall Survival
9%
Proportional Hazards Model
8%
Lymph Node Metastasis
7%
Diagnostic Accuracy
7%
Diagnosis
7%
Ionotropic Receptor
7%
Survival Rate
7%
Diabetes Mellitus
7%
Patient with Type 2 Diabetes
6%
Metastatic Carcinoma
6%
Apoplexy
6%
Middle Age
6%
Biological Product
5%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
43%
Randomized Controlled Trial
20%
Malignant Neoplasm
20%
Autoimmune Disease
19%
Sjoegren Syndrome
15%
Coronary Artery Aneurysm
14%
Non Insulin Dependent Diabetes Mellitus
14%
Mucocutaneous Lymph Node Syndrome
14%
Rheumatoid Arthritis
14%
Systemic Lupus Erythematosus
14%
Comorbidity
13%
Syndrome
13%
Overall Survival
11%
Autoantibodies
11%
Infection
11%
Cardiovascular Disease
10%
Immunoglobulin M
10%
Sleep Disordered Breathing
9%
Bisphosphonic Acid Derivative
9%
4 Hydroxynonenal
9%
Rheumatic Disease
9%
Probiotic Agent
9%
Influenza A Virus (H1N1)
9%
Head and Neck Squamous Cell Carcinoma
9%
Sepsis
9%
QT Prolongation
9%
Disease
9%
Breast Cancer
9%
Chemotherapy
9%
Isoniazid
9%
Placebo
8%
Survival Rate
8%
Rifampicin
7%
Adverse Event
7%
Hepatitis C
7%
Thromboembolism
7%
Hyperlipidemia
7%
Immunoglobulin A
7%
Ionotropic Receptor
7%
Interleukin 10
7%
Quinolone Derivative
6%
Drug Resistant Tuberculosis
6%
Prevalence
6%
Vaccination Policy
6%
Bacteremia
5%
Recurrent Disease
5%
Hemodialysis
5%
Absence
5%
Cytokine
5%
Thyroiditis
5%
Nursing and Health Professions
Meta Analysis
49%
Systematic Review
25%
Polyethylene Terephthalate
19%
Disease
16%
Health Care Cost
15%
Positron Emission Tomography-Computed Tomography
14%
Cohort Analysis
14%
Confidence Interval
14%
Diabetes Mellitus
11%
Malignant Neoplasm
10%
Symptom
9%
Fluorodeoxyglucose F 18
9%
Probiotic Agent
9%
Peritoneal Dialysis
9%
Breast Cancer
8%
Diagnosis
7%
Adverse Event
7%
Fluorine 18
6%
Prevalence
6%
Sensitivity and Specificity
6%
Imaging
6%
Placebo
6%
Health Care Utilization
5%
Odds Ratio
5%
Prospective Cohort Study
5%
Serum Albumin
5%
Receiver Operating Characteristic
5%
